ERYtech Pharma creates high value products for hospital market, mainly in hematology and oncology fields.

ERYtech Pharma has a first success with its lead compound Graspa® which demonstrated positive results and excellent safety profile compared to control treatment in Phase II trials in acute lymphoblastic leukaemia. Phase III in leukaemia will start in 2009 and a development program of Graspa® in several other indications notably solid tumors is ongoing.

Headquartered in France with a cGMP manufacturing unit, ERYtech Pharma has a US Office and a US location for cGMP clinical batches production in partnership with the American Red Cross.

ERYtech Pharma’s business & revenue model is both:

• An integrated business & revenue model for proprietary product to maximize value creation
• A business development partnership revenue model

 

Main achievements and highlights:

 2010

• FDA grants Orphan Drug Designation to GRASPA® for treatment of Acute Lymphoblastic Leukaemia

2009

• Pivotal Clinical Trial for GRASPA® in Acute Lymphoblastic Leukaemia in Europe
• Phase II Clinical Trial with GRASPA® as first-line treatment among patients with Acute Lymphoblastic Leukaemia aged 55 and older
• cGMP facility certification from the French Health Products Safety Agency (AFSSAPS)
• American Red Cross manufacturing and supply agreements
• ISO 9001:2008 certification
• Granted by the French Ministry of Research
• Supervisory Board and Scientific Board reinforced

2008

• Phase I/II Clinical Trial for GRASPA®: last patient enrolled and results presented at the 50th Annual Meeting of the American Society of Hematology (ASH) in San Francisco
• Granted by France's National Research Agency and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA)

 2007

• Phase I/II Clinical Trial for GRASPA®: launching in Belgium
• New Headquarters, R&D laboratory and cGMP facility in Lyon

2006

• Phase I/II Clinical Trial for GRASPA®: first patient enrolled
• EMEA awards Medicinal Product classification for GRASPA®
• EMEA awards Orphan Drug Designation for GRASPA®
• Financing round A € 12 million

 2005

• Seed Financing Round € 750.000 with financial shareholders and business angels
• Granted by the French Ministry of Research, France's National Research Agency, Rhône-Alpes Région and the Lyon Auvergne Rhône-Alpes Cancer Research Cluster (CLARA)

 2004

• ERYtech Pharma incorporation
• Granted by the French Ministry of Research and award from the Rhône-Alpes Ouest Créalys business incubator